Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine

Inactive Publication Date: 2015-06-25
BIONOR IMMUNO
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention presents a method to reduce the risks of developing human retrovirus infection, such as HIV, by combining the effects of therapeutic vaccines, immunomodulatory compounds, and reservoir purging agents. This approach aims to stimulate both the humoral and cell-mediated immune responses in a subject. The technical effect of this invention is to provide a more effective way to protect against human retrovirus infection.

Problems solved by technology

It is these latent reservoirs that represent the major challenge to eradication of HIV-1 infection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine
  • Vaccine
  • Vaccine

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0226]Peptides to be used according to the present invention that elicit Cell-mediated immunity (CMI) or peptides that stimulate the humoral immunity in a subject were synthesized using conventional techniques for linear sequences as described in international patent applications WO0052040, WO 2012 / 092934 or WO 2012 / 072088.

[0227]Specifically compounds to stimulate the humoral immunity in a subject by inducing antibodies that stabilise association of the C5 domain of HIV gp120 with the transmembrane domain of gp41 and / or with the constant C2 domain of gp120 were prepared as described in WO2011 / 000962.

[0228]Also compounds to stimulate the humoral immunity in a subject by stabilising the association of the C5 domain of HIV gp120 with the transmembrane domain of gp41 and / or with the constant C2 domain of gp120 were prepared as described in WO2011 / 000962.

[0229]Immunomodulatory compound and a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor used according to the pre...

example 2

[0439]A vaccine comprising the peptides of the SEQ ID NO:49, 52, 57 and 64 was prepared. The freeze-dried peptides are dissolved in sterile water at a final concentration of 4 mg / ml. The final salt concentration was 0.9%. A preparation of a granulocyte-macrophage-colony stimulating factor (GM-CSF) was also prepared, according to the manufacturers directions for use, to a final concentration of 0.3 mg / ml. The two solutions are administered intracutaneously. A typical injection dose is 100 μl.

example 3

[0440]An antigen solution or suspension is mixed with equal parts of Freund's adjuvant of Behring, complete or incomplete, and is then finely emulsified by being drawn up into, and vigorously pressed out of, an injection syringe, or with a homogenator. The emulsion should remain stable for at least 30 minutes. The antigen-adjuvant emulsions is best injected subcutaneously as a depot.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and / or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and / or a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor.

Description

FIELD OF THE INVENTION[0001]The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel methods of treatments with combinations of a compound to stimulate the humoral immunity and / or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and / or reservoir purging agents, such as a histone deacetylase (HDAC) inhibitors.BACKGROUND OF THE INVENTION[0002]In recent years a large body of research evidence has accumulated supporting the concept that AIDS is an immunological disease induced by HIV-1 rather than simply being caused by loss of CD4+ T-lymphocytes as a result of chronic cytopathic viral infection. It is therefore important to develop interventions that also target the chronic immune stimulation induced by HIV-1 (Sommerfelt 2011, Recent Translational Research in HIV / AIDS Ed. Dr. Yi-Wei Tang....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/21A61K45/06A61K31/454
CPCA61K39/21C12N2740/16034A61K45/06A61K31/454A61K31/429A61K31/675C07K14/162A61K2039/55566A61K39/12A61K47/60A61K38/15A61P31/18A61P43/00A61K2300/00C12N7/00A61K39/42
Inventor HOIE, LARSLUNDEMOSE, ANKEROKVIST, MATSHOVDEN, ARNT OVEGRONVOLD, MAJA SOMMERFELTHANSEN, VIDAR WENDELSORENSEN, BIRGER
Owner BIONOR IMMUNO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com